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To the Editor: 
 
We read with great interest the study of Dr. Kessler et al. [1] related to our 
article published in Liver International [2]. We thank the authors for their kind 
interest in our work and welcome their results that support our finding and 
also for giving a rational clue to further clarify the significance of ficolin 
molecules in cirrhosis-associated bacterial infections.  
 In our study low levels of L-ficolin (Liver ficolin, ficolin-2 [FCN-2]) and 
H-ficolin (Hakata ficolin, ficolin-3 [FCN-3] were associated with immune 
dysfunction in cirrhosis resulting in the development of clinically significant 
bacterial infections. Likewise, Ulf et al. found reduced L-ficolin levels in a non-
cirrhotic patient population with sepsis. Stability of the L-ficolin in both patient 
populations supports the fact that low levels of the molecule precede the 
development of bacterial infections and are rather the cause than the 
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consequence of these episodes and associated complications. More 
interestingly, levels of L-ficolin were significantly lower in patients with severe 
sequential organ failure assessment (SOFA)-score that warrants further 
studies in patients with cirrhosis. It is worthy defining the role of ficolins in the 
development of acute-on-chronic liver failure (ACLF) directly during the acute 
decompensation episodes associated with bacterial infection [3]. This issue 
was not evaluated in our cohort.  
 In patients with cirrhosis, development of bacterial infections increases 
mortality by four-fold despite of proper and timely administered antibiotic 
therapy [4]. Besides preventive strategies, supportive non-antibiotic 
medication(s) during episodes with bacterial infections would be of clinical 
utility. Up to now no supplementary medical treatment is known that is able to 
improve survival in cirrhosis-related infections. In a recent randomized 
controlled trial, albumin infusion failed to improve short-term survival in 
cirrhotic patients with infections other than SBP [5]. If low levels of ficolins turn 
out to show association with the development of ACLF and infection-related 
mortality, the possible benefit of ficolin supplementation should be further 
investigated. Feasibility of this approach might be verified by the reported data 
that restoration of mannose binding lectin (MBL)-deficiency with MBL 
substitution either by plasma derived (pdMBL) or recombinant (rMBL) protein 
proved to be viable, safe and effective in both pre-clinical studies and early 
phase II trials in non-cirrhotic patient population [6]. 
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article published in Liver International [2]. We thank the authors for their kind 
interest in our work and welcome their results that support our finding and 
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utility. Up to now no supplementary medical treatment is known that is able to 
improve survival in cirrhosis-related infections. In a recent randomized 
controlled trial, albumin infusion failed to improve short-term survival in 
cirrhotic patients with infections other than SBP [5]. If low levels of ficolins turn 
out to show association with the development of ACLF and infection-related 
mortality, the possible benefit of ficolin supplementation should be further 
investigated. Feasibility of this approach might be verified by the reported data 
that restoration of mannose binding lectin (MBL)-deficiency with MBL 
substitution either by plasma derived (pdMBL) or recombinant (rMBL) protein 
proved to be viable, safe and effective in both pre-clinical studies and early 
phase II trials in non-cirrhotic patient population [6]. 
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